Abstract 6060: Patient-derived models of primary breast cancer for preclinical evaluation of neoadjuvant therapies

Le résumé fourni par la source

Abstract Targeted therapies are important for invasive breast cancer (IBC) treatment but are generally not standard-of-care in the neoadjuvant setting. To identify therapies with the potential to improve neoadjuvant treatment response, it is essential to develop patient-derived preclinical models that faithfully reflect the diversity of primary IBC subtypes in patients. Here, we collected data of all breast cancer patients (N=1675) diagnosed in the Antoni van Leeuwenhoek hospital (AVL) for a period of three years, while simultaneously receiving tissue samples of 314 patients to establish a collection of mouse-intraductal patient-derived xenograft (MIND-PDX) models fully recapitulating the heterogeneity of primary IBC. Serial transplantation of lesions resulted in the first large-scale cohort of 60 transplantable IBC-MIND models, comprising 31 luminal (i.e., ER+/HER-), 5 HER2+ and 24 TN models, as well as 7 matching PDX organoid (PDXO) models. We show that our IBC-MIND cohort can serve as a platform for preclinical evaluation of experimental neoadjuvant treatments. For triple-negative IBC, we demonstrate that neoadjuvant treatment does not benefit from addition of a PARP inhibitor, while for estrogen receptor (ER) positive IBC the combination of a CDK4/6 inhibitor and fulvestrant improves neoadjuvant treatment response. Our work provides a valuable resource of primary IBC models to study breast cancer biology and develop novel neoadjuvant treatments. Citation Format: Stefan J. Hutten, Xue Chao, Madelon Badoux, Timo Eijkman, Michael Sheinman, Roebi de Bruijn, Andrea Herencia-Ropero, Alba Llop-Guevara, Catrin Lutz, Jelle Wesseling, Violeta Serra, Jacco Van Rheenen, Colinda LGJ Scheele, Jos Jonkers. Patient-derived models of primary breast cancer for preclinical evaluation of neoadjuvant therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6060.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.